Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

COR Therapeutics discloses factor Xa inhibitors

Feb. 18, 1997

Comparative study of second-generation t-PA inhibitor and alteplase

Feb. 17, 1997

Anti-factor Xa compounds disclosed by RPR

Feb. 14, 1997

ZymoGenetics/Novo Nordisk isolate anticlotting agent

Feb. 14, 1997

FDA approves product for hemophilia

Feb. 13, 1997

Roberts receives approvable letter from FDA for Agrylin

Feb. 12, 1997

Potent gpIIb/IIIa antagonist synthesized using combinatorial techniques

Feb. 11, 1997

NIH funds development of antiplatelet agents from Cypress/PRP

Feb. 7, 1997

BASF discloses antithrombotic from ticks

Feb. 6, 1997

COR Therapeutics' cardiovascular drug candidate enters phase I trials

Feb. 5, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 31, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026